Sign in

CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
813879991
Phone
617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. DEF 14A Proxy Proxy Statement
  2. 4 Open-market sale Chief Medical Officer sold 4,895 shares at $8.53 ($41,754)
  3. 4 Open-market sale President and CEO sold 12,529 shares at $8.53 ($106,872)
  4. 4 Open-market sale Chief Scientific Officer sold 3,756 shares at $8.53 ($32,039)
  5. 4 Open-market sale Chief Legal Officer sold 3,756 shares at $8.53 ($32,039)
  6. S-8 Other Securities Offered to Employees in Benefit Plans
  7. 10-K Report Annual Report
  8. 8-K Event Results of operations
  9. 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
  10. 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
  11. 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)
  12. 4 Grant or award President and CEO acquired 180,000 shares (grant or award)
  13. 4 Grant or award Chief Medical Officer acquired 65,000 shares (grant or award)
  14. 4 Grant or award Chief Financial Officer acquired 60,000 shares (grant or award)
  15. 8-K Event Regulation FD disclosure · Other events
  16. 4 Planned sale Chief Scientific Officer sold 4,000 shares at $12.51 ($50,040)
  17. 144 Insider Sale of Securities
  18. 4 Open-market sale President and CEO sold 8,400 shares at $11.87 ($99,708)
  19. 4 Open-market sale Chief Scientific Officer sold 4,693 shares at $11.41 ($53,547)
  20. 4 Open-market sale Chief Medical Officer sold 4,632 shares at $11.41 ($52,851)

Page 7 of 24 · 471 filings